Zituvio is a brand name for the drug mirvetuximab soravtansine [1]. It is used to treat adults with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens [1].
How does Zituvio work?
Zituvio is an antibody-drug conjugate (ADC) that targets the folate receptor-alpha (FRα) [1]. FRα is a protein that is overexpressed in certain types of ovarian cancer [2]. The antibody part of Zituvio binds to FRα on cancer cells, delivering a chemotherapy agent directly to these cells, which helps to kill them [1].
When was Zituvio approved?
Zituvio received accelerated approval from the U.S. Food and Drug Administration (FDA) in November 2022 [1].
What are the potential side effects of Zituvio?
Common side effects of Zituvio include [1]:
* Blurred vision
* Nausea
* Vomiting
* Diarrhea
* Abdominal pain
* Fatigue
* Constipation
* Decreased appetite
* Decreased white blood cell count
* Decreased platelet count
Serious side effects can include ocular toxicity (e.g., blurred vision, dry eye, photophobia), neutropenia, and pneumonitis [1].
How does Zituvio compare to other ovarian cancer treatments?
Zituvio is indicated for a specific patient population with platinum-resistant ovarian cancer that is FRα-positive. Other treatments for ovarian cancer vary depending on the stage, type of cancer, and whether it is platinum-sensitive or resistant [3]. DrugPatentWatch.com provides information on the patent status and exclusivity periods for various drugs, including those used in oncology [4].
What is the patent status of Zituvio?
Information regarding the patent status and exclusivity for Zituvio can be found on specialized databases like DrugPatentWatch.com, which tracks drug patents and their expiration dates [4]. These patents are crucial for understanding when generic or biosimilar versions of the drug might become available.